Amgen Inc. (AMGN)

$287.87

+7.92

(+2.83%)▲

Market is closed - opens 8 PM, 21 Nov 2024
star icon

Amgen, Inc. is a biopharmaceutical company that is involved in the development and commercialization of drugs for various diseases.

Performance

  • $279.04
    $288.45
    $287.87
    downward going graph

    3.07%

    Downside

    Day's Volatility :3.26%

    Upside

    0.2%

    downward going graph
  • $260.52
    $346.85
    $287.87
    downward going graph

    9.5%

    Downside

    52 Weeks Volatility :24.89%

    Upside

    17.0%

    downward going graph

Returns

PeriodAmgen Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-12.54%
-7.6%
5.8%
6 Months
-8.57%
-2.3%
12.7%
1 Year
9.53%
10.1%
33.6%
3 Years
42.0%
7.5%
18.1%

Highlights

Market Capitalization
150.5B
Book Value
$14.00
Dividend Share
8.88
Dividend Yield
3.21%
Earnings Per Share (EPS)
7.84
PE Ratio
35.71
PEG Ratio
2.01
Wall Street Target Price
334.06
Profit Margin
13.0%
Operating Margin TTM
24.16%
Return On Assets TTM
4.6%
Return On Equity TTM
55.72%
Revenue TTM
32.5B
Revenue Per Share TTM
60.64
Quarterly Revenue Growth YOY
23.200000000000003%
Gross Profit TTM
19.9B
EBITDA
12.2B
Diluted Eps TTM
7.84
Quarterly Earnings Growth YOY
0.62
EPS Estimate Current Year
19.56
EPS Estimate Next Year
20.63
EPS Estimate Current Quarter
5.11
EPS Estimate Next Quarter
5.46

Analyst Recommendation

Buy
    56%Buy
    35%Hold
    8%Sell
Based on 37 Wall street analysts offering stock ratings for Amgen Inc.(by analysts ranked 0 to 5 stars)
Based on 37 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
21
21
22
Hold
13
13
10
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 16.05%

Current $287.87
Target $334.06

Company Financials

FY18Y/Y Change
Revenue
23.7B
↑ 3.93%
Net Income
8.4B
↑ 324.15%
Net Profit Margin
35.35%
↑ 26.69%
FY19Y/Y Change
Revenue
23.4B
↓ 1.62%
Net Income
7.8B
↓ 6.58%
Net Profit Margin
33.57%
↓ 1.78%
FY20Y/Y Change
Revenue
25.4B
↑ 8.83%
Net Income
7.3B
↓ 7.37%
Net Profit Margin
28.57%
↓ 5.0%
FY21Y/Y Change
Revenue
26.0B
↑ 2.18%
Net Income
5.9B
↓ 18.87%
Net Profit Margin
22.68%
↓ 5.89%
FY22Y/Y Change
Revenue
26.3B
↑ 1.32%
Net Income
6.6B
↑ 11.18%
Net Profit Margin
24.89%
↑ 2.21%
FY23Y/Y Change
Revenue
28.2B
↑ 7.09%
Net Income
6.7B
↑ 2.52%
Net Profit Margin
23.83%
↓ 1.06%
Q2 FY23Q/Q Change
Revenue
7.0B
↑ 14.43%
Net Income
1.4B
↓ 51.46%
Net Profit Margin
19.74%
↓ 26.8%
Q3 FY23Q/Q Change
Revenue
6.9B
↓ 1.19%
Net Income
1.7B
↑ 25.45%
Net Profit Margin
25.06%
↑ 5.32%
Q4 FY23Q/Q Change
Revenue
8.2B
↑ 18.73%
Net Income
767.0M
↓ 55.66%
Net Profit Margin
9.36%
↓ 15.7%
Q1 FY24Q/Q Change
Revenue
7.4B
↓ 9.76%
Net Income
-113.0M
↓ 114.73%
Net Profit Margin
-1.53%
↓ 10.89%
Q2 FY24Q/Q Change
Revenue
8.3B
↑ 12.67%
Net Income
746.0M
↓ 760.18%
Net Profit Margin
8.95%
↑ 10.48%
Q3 FY24Q/Q Change
Revenue
8.5B
↑ 2.04%
Net Income
2.8B
↑ 279.36%
Net Profit Margin
33.28%
↑ 24.33%
FY18Y/Y Change
Total Assets
66.4B
↓ 16.93%
Total Liabilities
53.9B
↓ 1.46%
FY19Y/Y Change
Total Assets
59.7B
↓ 10.1%
Total Liabilities
50.0B
↓ 7.2%
FY20Y/Y Change
Total Assets
62.9B
↑ 5.43%
Total Liabilities
53.5B
↑ 7.01%
FY21Y/Y Change
Total Assets
61.2B
↓ 2.83%
Total Liabilities
54.5B
↑ 1.73%
FY22Y/Y Change
Total Assets
65.1B
↑ 6.47%
Total Liabilities
61.5B
↑ 12.84%
FY23Y/Y Change
Total Assets
97.2B
↑ 49.19%
Total Liabilities
90.9B
↑ 47.94%
Q2 FY23Q/Q Change
Total Assets
90.3B
↑ 1.75%
Total Liabilities
83.5B
↑ 0.14%
Q3 FY23Q/Q Change
Total Assets
90.5B
↑ 0.29%
Total Liabilities
82.9B
↓ 0.73%
Q4 FY23Q/Q Change
Total Assets
97.2B
↑ 7.31%
Total Liabilities
90.9B
↑ 9.71%
Q1 FY24Q/Q Change
Total Assets
93.0B
↓ 4.3%
Total Liabilities
88.0B
↓ 3.26%
Q2 FY24Q/Q Change
Total Assets
90.9B
↓ 2.23%
Total Liabilities
85.0B
↓ 3.38%
Q3 FY24Q/Q Change
Total Assets
90.9B
↓ 0.03%
Total Liabilities
83.4B
↓ 1.91%
FY18Y/Y Change
Operating Cash Flow
11.3B
↑ 1.06%
Investing Cash Flow
14.3B
↓ 456.34%
Financing Cash Flow
-22.5B
↑ 241.07%
FY19Y/Y Change
Operating Cash Flow
9.2B
↓ 19.0%
Investing Cash Flow
5.7B
↓ 60.19%
Financing Cash Flow
-15.8B
↓ 29.89%
FY20Y/Y Change
Operating Cash Flow
10.5B
↑ 14.72%
Investing Cash Flow
-5.4B
↓ 194.61%
Financing Cash Flow
-4.9B
↓ 69.13%
FY21Y/Y Change
Operating Cash Flow
9.3B
↓ 11.77%
Investing Cash Flow
733.0M
↓ 113.57%
Financing Cash Flow
-8.3B
↑ 69.94%
FY22Y/Y Change
Operating Cash Flow
9.7B
↑ 4.97%
Investing Cash Flow
-6.0B
↓ 924.56%
Financing Cash Flow
-4.0B
↓ 51.19%
FY23Y/Y Change
Operating Cash Flow
8.5B
↓ 12.86%
Investing Cash Flow
-26.2B
↑ 333.55%
Financing Cash Flow
21.0B
↓ 621.38%
Q2 FY23Q/Q Change
Operating Cash Flow
4.1B
↑ 286.18%
Investing Cash Flow
-211.0M
↓ 115.54%
Financing Cash Flow
-1.2B
↓ 105.63%
Q3 FY23Q/Q Change
Operating Cash Flow
2.8B
↓ 32.83%
Investing Cash Flow
-262.0M
↑ 24.17%
Financing Cash Flow
-2.0B
↑ 65.7%
Q4 FY23Q/Q Change
Operating Cash Flow
538.0M
↓ 80.51%
Investing Cash Flow
-27.1B
↑ 10239.31%
Financing Cash Flow
2.8B
↓ 237.36%
Q1 FY24Q/Q Change
Operating Cash Flow
689.0M
↑ 28.07%
Investing Cash Flow
-217.0M
↓ 99.2%
Financing Cash Flow
-1.7B
↓ 162.02%

Technicals Summary

Sell

Neutral

Buy

Amgen Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Amgen Inc.
Amgen Inc.
-9.11%
-8.57%
9.53%
42.0%
26.36%
Eli Lilly And Company
Eli Lilly And Company
-16.85%
-6.2%
27.14%
189.28%
556.57%
Johnson & Johnson
Johnson & Johnson
-5.97%
1.24%
1.32%
-4.13%
12.22%
Merck & Co. Inc.
Merck & Co. Inc.
-8.37%
-25.48%
-4.67%
19.35%
14.02%
Novo Nordisk A/s
Novo Nordisk A/s
-10.28%
-22.11%
2.42%
89.28%
289.6%
Abbvie Inc
Abbvie Inc
-10.07%
2.96%
20.93%
45.06%
93.9%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Amgen Inc.
Amgen Inc.
36.22
35.71
2.01
19.56
0.56
0.05
0.03
14.0
Eli Lilly And Company
Eli Lilly And Company
78.72
78.72
0.69
13.16
0.65
0.14
0.01
15.83
Johnson & Johnson
Johnson & Johnson
25.45
25.45
0.92
9.96
0.21
0.08
0.03
29.14
Merck & Co. Inc.
Merck & Co. Inc.
20.2
20.2
0.07
7.74
0.28
0.11
0.03
17.58
Novo Nordisk A/s
Novo Nordisk A/s
34.03
34.03
1.53
22.7
0.89
0.21
0.01
27.07
Abbvie Inc
Abbvie Inc
57.94
58.04
0.4
10.94
0.56
0.08
0.04
3.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Amgen Inc.
Amgen Inc.
Buy
$152.4B
26.36%
36.22
13.0%
Eli Lilly And Company
Eli Lilly And Company
Buy
$692.7B
556.57%
78.72
20.48%
Johnson & Johnson
Johnson & Johnson
Buy
$370.8B
12.22%
25.45
16.74%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$244.3B
14.02%
20.2
19.23%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$472.8B
289.6%
34.03
35.01%
Abbvie Inc
Abbvie Inc
Buy
$293.8B
93.9%
57.94
9.22%

Insights on Amgen Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 7.39B → 8.50B (in $), with an average increase of 6.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -113.0M → 2.83B (in $), with an average increase of 94.4% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 27.1% return, outperforming this stock by 17.6%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 189.0% return, outperforming this stock by 149.3%

Institutional Holdings

  • Vanguard Group Inc

    9.74%

  • BlackRock Inc

    8.57%

  • State Street Corp

    5.39%

  • Morgan Stanley - Brokerage Accounts

    5.34%

  • PRIMECAP Management Company

    2.65%

  • Geode Capital Management, LLC

    2.24%

Corporate Announcements

  • Amgen Inc. Dividends March,2024

    In the quarter ending March,2024. Amgen Inc. has declared dividend of $2.25

    Read More

Company Information

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

Organization
Amgen Inc.
Employees
26700
CEO
Mr. Robert A. Bradway
Industry
Health Technology

FAQs